Scott Morenstein Net Worth

Scott Morenstein biography

Scott D. Morenstein serves as Independent Director of the Company. Mr. Morenstein serves as Managing Director of CAM Capital, where he leads healthcare investing. CAM Capital was established in 2012 by Bruce Kovner following his retirement from Caxton Associates, the macro hedge fund he founded and managed from 1983 to 2011. Prior to joining CAM Capital in 2013, Mr. Morenstein served as Managing Director at Valence Life Sciences and before that Principal at Caxton Advantage Venture Partners, which he joined in 2007. Prior to joining Caxton Advantage, Mr. Morenstein served as an investment banking associate and founding member of Seaview Securities. Mr. Morenstein began his career at Lehman Brothers as a healthcare investment banker and equity research analyst. Mr. Morenstein has more than 15 years’ experience in biopharmaceutical investing, equity research and investment banking. Mr. Morenstein led CAM’s investment in and served as a director of Celator Pharmaceuticals until its acquisition by Jazz Pharmaceuticals in July 2016. He was nominated a director of Synta Pharmaceuticals to advise the company as it explored strategic alternatives ultimately leading to a merger with Madrigal Pharmaceuticals. He served as a member of the board of directors of Gemin X Pharmaceuticals until its acquisition by Cephalon. He currently serves as a director of Velicept Therapeutics and Antios Therapeutics. Mr. Morenstein received an M.B.A. from Harvard Business School and a B.A. from the University of Pennsylvania with a degree in the Biological Basis of Behavior with a Concentration in the Physiology of Neural Systems. Our Board has concluded that Mr. Morenstein should serve as a director of the Company based on Mr. Morenstein’s industry and financial expertise and experience.

What is the salary of Scott Morenstein?

As the Independent Director of Molecular Templates Inc, the total compensation of Scott Morenstein at Molecular Templates Inc is $150,052. There are 13 executives at Molecular Templates Inc getting paid more, with Eric Poma having the highest compensation of $1,733,740.

How old is Scott Morenstein?

Scott Morenstein is 44, he's been the Independent Director of Molecular Templates Inc since 2017. There are 17 older and 2 younger executives at Molecular Templates Inc. The oldest executive at Molecular Templates Inc is David Hoffmann, 75, who is the Independent Director.

What's Scott Morenstein's mailing address?

Scott's mailing address filed with the SEC is C/O CAXTON ALTERNATIVE MANAGEMENT LP, 1330 6TH AVENUE, 20TH FLOOR, NEW YORK, NY, 10019.

Insiders trading at Molecular Templates Inc

Over the last 7 years, insiders at Molecular Templates Inc have traded over $22,993,582 worth of Molecular Templates Inc stock and bought 14,744,530 units worth $82,519,716 . The most active insiders traders include Target N Vbb Biotech Ag Bio..., David Hirsch és Capital Partners Iii, Llc L.... On average, Molecular Templates Inc executives and independent directors trade stock every 47 days with the average trade being worth of $532,718. The most recent stock trade was executed by Target N Vbb Biotech Ag Bio... on 2 April 2024, trading 250,000 units of MTEM stock currently worth $587,500.

What does Molecular Templates Inc do?

molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.

Molecular Templates Inc executives and stock owners

Molecular Templates Inc executives and other stock owners filed with the SEC include:

• Eric Poma,
  Chief Executive Officer, Chief Scientific Officer, Director
• Roger Waltzman,
  Chief Medical Officer
• Jason Kim,
  President, Chief Operating Officer
• Adam Cutler,
  Chief Financial Officer, Treasurer, Secretary
• Dr. Eric E. Poma,
  CEO, Chief Scientific Officer & Director
• Dr. Roger J. Waltzman M.B.A., M.D.,
  Chief Medical Officer
• Jason S Kim,
  Pres & COO
• Dr. Roger J. Waltzman,
  Chief Medical Officer
• Corazon Sanders,
  Independent Director
• Harold Selick,
  Chairman of the Board
• Kevin Lalande,
  Independent Director
• David Hirsch,
  Independent Director
• David Hoffmann,
  Independent Director
• Scott Morenstein,
  Independent Director
• Jonathan Lanfear,
  Independent Director
• Michael Dowd,
  Sr. VP of Project & Alliance Management
• Megan C. Filoon,
  Gen. Counsel & Sec.
• Dr. Nenad Sarapa M.D., M.S.,
  Sr. VP of Clinical Devel.
• Dr. Jen-Sing Liu Ph.D.,
  Exec. VP of Manufacturing
• Dr. Erin Willert Ph.D.,
  Exec. VP of R&D
• Dr. Jack Higgins Ph.D.,
  Exec. VP of Operations & Head of Manufacturing
• Kurt Elster,
  Exec. VP of Corp. Devel.
• Sean McLennan,
  Sr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & Treasurer
• Associates, L.L.C.Morenstei...,
  
• Target N Vbb Biotech Ag Bio...,
  
• Dave Hoffmann,
  Director
• Capital Partners Iii, Llc L...,
  
• Scott Dcdk Associates, L.L....,
  
• Management Services, Llc Cu...,
  
• Sean Mc Lennan,
  See remarks
• Management Services, Llc Cu...,
  
• Gabriela Gruia,
  Director
• Maurizio Voi,
  Chief Medical Officer